A Phase Ii, Multicenter, Randomized, Open-Label Study To Evaluate The Safety And Tolerability Of Proxalutamide (Gt0918) In Subjects With Metastatic Castrate-Resistant Prostate Cancer (Mcrpc).

Tie Zhou,Dingwei Ye,Zhongquan Sun,Qinggui Meng,Dalin He,Guowei Shi,Jie Jin,Weibing Sun,Lijun Chen,Ben Liu,Jingen Wang,Jiwen Cheng,Zhiquan Hu, Yong Yang,Xishuang Song,Yinhuai Wang,Cheng Fu,Qiaoxia Zhou,Youzhi Tong,Ying-Hao Sun

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览18

暂无评分

摘要

108Background: GT0918 is a 2nd generation of AR antagonist and capability to down-regulate AR level. This study is an open-label, randomized, multicenter, Ph II study to evaluate the safety and eff...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要